Document is current
Any future updates will be listed below
-
Authors
Obling, Laust E. R. http://orcid.org/0000-0003-2927-3670
Beske, Rasmus P.
Meyer, Martin A. S.
Grand, Johannes
Wiberg, Sebastian
Mohr, Thomas
Damm-Hejmdal, Anders
Forman, Julie L.
Frikke-Schmidt, Ruth
Folke, Fredrik
Møller, Jacob E.
Kjaergaard, Jesper
Hassager, Christian
-
Funding
Funding for this research was provided by:
Research Foundation of Rigshospitalet (E-22652-04)
Novo Nordisk Fonden (NNF20OC0064043)
Copenhagen University
- License Information
-
More Information
Article History
Received: 4 December 2023
Accepted: 12 January 2024
First Online: 22 January 2024
Declarations
:
: Before commencing the trial, approvals were secured from the Regional Ethics Committee (ID: H-20022320) and the Danish Medicines Agency (ID: 2020033425). Additionally, a legal data handling agreement received approval from the Capital Region of Denmark (ID: P-2020-866). The STEROHCA trial adhered to the principles outlined in the Declaration of Helsinki. Prior to inclusion, written consent was acquired from a primary trial guardian and later verified by a secondary trial guardian. Efforts were made to secure written informed consent from the closest relatives upon hospital admission, and subsequently, consent was sought from all patients upon the restoration of their decision-making capacity.
: Not applicable.
: The salary of the corresponding author (LERO) was funded through a grant from the Research Foundation of Rigshospitalet (E-22652-04). The study, inclusive of RPB's salary, received support from a grant provided by the Novo Nordisk Foundation (NNF20OC0064043) under the auspices of CH. CH also benefits from an unrestricted grant from the Lundbeck Foundation (R186-2015-2132), received a speaker honorarium from Abiomed during the study, and holds positions as a board member of the European Society of Cardiology and chair of the Danish Heart Foundation. JK is backed by an unrestricted grant from the Novo Nordisk Foundation (NNF17OC0028706) and serves on two Data Safety Monitoring Boards for the IVIO trial (as chair) and the COCA trial, without any financial compensation. JEM received research grants from Abiomed and Novo Nordisk Foundation outside the current study, speaker honorariums from Abiomed, Abbott, and Boehringer Ingelheim, and attended meetings with support from Abiomed. FF is supported by a research grant from the Novo Nordisk Foundation (NNF19OC0055142). RFS received grants from the Lundbeck Foundation, Danish Heart Foundation, and Sygeforsikringen Danmark Research Fund, all unrelated to the present study. The remaining authors have no disclosures to report.
